TORONTO, ON / ACCESSWIRE / December 3, 2019 / Soricimed, a privately-held, science-based company focused on the development and commercialization of drug candidates for the treatment of solid-tumor cancers, environmentally responsible pesticides and novel active skin-care products, announced today that management will present an update on the Company’s business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 1:30 p.m. Eastern Time.
The live and archived presentation webcast can be accessed here.
About Soricimed Biopharma Inc.: Soricimed is a privately-held, science-based company focused on the development and commercialization of applications originally derived from its unique and proprietary family of peptides found in the paralytic venom of the northern short-tailed shrew. Product development is ongoing for three distinct verticals: as targeted drug candidates for the treatment of solid-tumor cancers; as an environmentally responsible pesticide for the agriculture and aquaculture sectors; and as novel active ingredients in skin-care products for the cosmetic industry. For more information visit www.soricimed.com.
Media Relations:
Julie A. Fotheringham
Partner, HAGEMAN Communications
Julie.fotheringham@hageman.ca
416.951.7988
Investor Relations:
Stephen Kilmer
President, Kilmer Lucas Inc.
stephen@kilmerlucas.com
646.274.3580
SOURCE: Soricimed Biopharma
View source version on accesswire.com:
https://www.accesswire.com/568702/Soricimed-to-Present-at-the-First-Annual-BioTuesdays-Pre-JPM-Virtual-Conference
TAMPA, Fla., March 27, 2024 /PRNewswire/ -- Greenway Health, a leading health information technology services provider, announced its strategic…
List Based on an Independent Survey of 25,000 U.S. ResidentsREMOTE-FIRST COMPANY/NEW YORK--(BUSINESS WIRE)--#NextGenHealthcare--NextGen Healthcare, a…
Fuller will help drive the growth and innovation of strategic communications firmCARLSBAD, Calif.--(BUSINESS WIRE)--#AppointmentNews--Ford Hutman…
Microsoft Azure customers worldwide can now purchase Lightbeam’s care orchestration technology suite directly from the…
General Catalyst leads funding round joined by .406 Ventures, Valtruis, Mass General Brigham Ventures, and…
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a…